Program
Probiotic
Also written as “Probiotic (Inersan)”, “R-2487” and “Probiatop”.
Its studies are mostly in Chronic Periodontitis · Sjogren's Syndrome · Depression · Signs and Symptoms, Digestive · Irritable Bowel Syndrome, led by 11 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CD Pharma India Pvt. | 30 open or running | phase 3since Jun 3, 2013 | Jun 3, 2013 | none ahead |
| Next Gen Pharma India Pvt. | 20 open or running | phase 3since Feb 3, 2015 | Feb 3, 2015 | none ahead |
| AbbVie | 10 open or running | phase 2since Nov 2, 2007 | Nov 2, 2007 | none ahead |
| Azidus Brasil | 10 open or running | phase 4since Oct 20, 2022 | Oct 20, 2022 | none ahead |
| GenMont Biotech Incorporation | 10 open or running | phase 2since Sep 22, 2020 | Sep 22, 2020 | none ahead |
| International Flavors & Fragrances | 10 open or running | phase 2since Aug 30, 2019 | Aug 30, 2019 | none ahead |
| Kaneka | 10 open or running | phase 1since Feb 26, 2018 | Feb 26, 2018 | none ahead |
| Kerry Group | 10 open or running | phase 1since Nov 14, 2019 | Nov 14, 2019 | none ahead |
| Lallemand Health Solutions | 11 open or running | phase 4since Jul 1, 2022 | Jul 1, 2022 | none ahead |
| Moon (Guangzhou) Biotechnology | 11 open or running | no phasesince Dec 30, 2025 | Dec 30, 2025 | Dec 30, 2026NCT07331987 |
| Rise Therapeutics | 11 open or running | phase 1since Feb 28, 2024 | Feb 28, 2024 | Aug 30, 2029phase 1 · NCT06297213 |
Also a collaborator on its studies: farmoquimica-s-a, icon-plc and 4pharma-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Nov 2, 2007.
- Jun 3, 2013CD Pharma India Pvt.'s first study: phase 3 study in Chronic PeriodontitisNew to CD Pharma India Pvt.CD Pharma India Pvt. · NCT01870362 · 28 enrolled · India
- Apr 22, 2014Phase 3 study in Chronic PeriodontitisCD Pharma India Pvt. · NCT02121665 · 42 enrolled · India
- Jul 28, 2014Phase 3 study in Lymphoma, FollicularCD Pharma India Pvt. · NCT02203812 · 32 enrolled · India
- Feb 3, 2015Next Gen Pharma India Pvt.'s first study: phase 3 study in MalocclusionNew to Next Gen Pharma India Pvt.Next Gen Pharma India Pvt. · NCT02357771 · 30 enrolled · India
- Mar 11, 2015Phase 3 study in Chronic PeriodontitisNext Gen Pharma India Pvt. · NCT02390687 · 31 enrolled · India
- Feb 26, 2018Kaneka's first study: phase 1 study in CariesNew to KanekaKaneka · NCT03468842 · 76 enrolled · Spain
- Aug 30, 2019International Flavors & Fragrances's first study: phase 2 study in Stress, PsychologicalNew to International Flavors & FragrancesInternational Flavors & Fragrances · NCT04125810 · 190 enrolled · Ireland, United Kingdom
- Nov 14, 2019Kerry Group's first study: phase 1 study in Streptococcus AgalactiaeNew to Kerry GroupKerry Group · NCT04165551 · 3 enrolled · Spain
- Sep 22, 2020GenMont Biotech Incorporation's first study: phase 2 study in Skin ProblemsNew to GenMont Biotech IncorporationGenMont Biotech Incorporation · NCT04566549 · 21 enrolled · Taiwan
- Jul 1, 2022Lallemand Health Solutions's first study: phase 4 study in Irritable Bowel SyndromeNew to Lallemand Health SolutionsLallemand Health Solutions · NCT05509725 · 162 planned · Turkey
- Oct 20, 2022Azidus Brasil's first study: phase 4 study in Signs and Symptoms, DigestiveNew to Azidus BrasilAzidus Brasil · NCT05603403 · 150 enrolled · Brazil
- Feb 28, 2024Rise Therapeutics's first study: phase 1 study in Sjogren's SyndromeNew to Rise TherapeuticsRise Therapeutics · NCT06297213 · 36 planned · United States
- Dec 30, 2025Moon (Guangzhou) Biotechnology's first study: no phase study in DepressionNew to Moon (Guangzhou) BiotechnologyMoon (Guangzhou) Biotechnology · NCT07331987 · 60 planned · China
- Oct 8, 2026Phase 1 study terminatedStudy stoppedNCT04165551 · “The study was terminated due to low enrollment”
Ahead
- Dec 30, 2026Primary completion: no phase study in DepressionMoon (Guangzhou) Biotechnology · NCT07331987
- Aug 30, 2029Primary completion: phase 1 study in Sjogren's SyndromeRise Therapeutics · NCT06297213
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07331987Depression · China | – | Recruiting | Moon (Guangzhou) Biotechnology | Dec 30, 2026 | 60 |
| NCT06297213Sjogren's Syndrome · United States | 1 | Not yet recruiting | Rise Therapeutics | Aug 30, 2029 | 36 |
| NCT05603403Signs and Symptoms, Digestive · Brazil | 4 | Completed | Azidus Brasil | Mar 15, 2023 | 150 |
| NCT05509725Irritable Bowel Syndrome · Turkey | 4 | Recruiting | Lallemand Health Solutions | Nov 2024 | 162 |
| NCT04566549Skin Problems · Taiwan | 2 | Completed | GenMont Biotech Incorporation | Dec 6, 2020 | 21 |
| NCT04165551Streptococcus Agalactiae · Spain | 1 | Terminated | Kerry Group | Sep 1, 2020 | 3 |
| NCT04125810Stress, Psychological · Ireland, United Kingdom | 2 | Completed | International Flavors & Fragrances | Feb 7, 2020 | 190 |
| NCT03468842Caries · Spain | 1 | Completed | Kaneka | Mar 24, 2017 | 76 |
| NCT02390687Chronic Periodontitis · India | 3 | Completed | Next Gen Pharma India Pvt. | Sep 2016 | 31 |
| NCT02357771Malocclusion · India | 3 | Completed | Next Gen Pharma India Pvt. | Aug 2015 | 30 |
| NCT02203812Lymphoma, Follicular · India | 3 | Completed | CD Pharma India Pvt. | Feb 2016 | 32 |
| NCT02121665Chronic Periodontitis · India | 3 | Completed | CD Pharma India Pvt. | Jan 2016 | 42 |
| NCT01870362Chronic Periodontitis · India | 3 | Completed | CD Pharma India Pvt. | Jul 2014 | 28 |
| NCT00554099Diverticulitis · United States | 2 | Completed | AbbVie | Mar 2010 | 117 |
How it is read
Names in the registry
- “Probiotic”, 6 entries
- “Probiotic (Inersan)”, 2 entries
- “R-2487”, 1 entry
- “Probiatop”, 1 entry
- “Probiotic formulation”, 1 entry
Conditions, from the studies’ own filings
- Chronic Periodontitis, 3 studies
- Sjogren's Syndrome, 1 study
- Depression, 1 study
- Signs and Symptoms, Digestive, 1 study
- Irritable Bowel Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.